HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.

Abstract
Antisense oligonucleotides have been used to target regulatory proteins in both in vivo and in vitro models of prostate cancer. Our previous studies showed that oligonucleotide-treated LNCaP prostate cancer cells compensate for diminished expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), an apoptosis inhibitor, by suppressing the expression of caspase-3 (an apoptosis promoter) while enhancing that of serine/threonine protein kinase (AKT1) (another apoptosis inhibitor). In addition, we found an enhanced expression of the androgen receptor (AR), its p300 and interleukin-6 (IL6) co-activators, polymerase transcription mediator (MED12), and growth-regulating signal transducer (STAT3). The net result was an altered pattern of gene expression often associated with more aggressive and proliferative tumors. To further evaluate adaptive compensatory mechanisms related to tumor resistance, aggression and proliferation, herein we evaluated the level of expression of a proliferation antigen (KI-67) and mitosis-regulating cyclins (B1 and D1). Compared to the relative levels of compensation detailed above, we found the expression of KI-67 to be statistically the most enhanced non-targeted protein yet identified in compensation for suppression of BCL2. Expression of cyclin D1 was also significantly enhanced, although to a much lesser extent. As a result, we propose that oligonucleotide-mediated treatment could be more effective when directed towards KI-67 and BCL2. This could be accomplished by dual monospecific targeting KI-67 and BCL2, or with a bispecific (or proposed multispecific) oligonucleotide simultaneously targeting both.
AuthorsMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
JournalIn vivo (Athens, Greece) (In Vivo) 2015 Nov-Dec Vol. 29 Issue 6 Pg. 687-93 ISSN: 1791-7549 [Electronic] Greece
PMID26546525 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Chemical References
  • Apoptosis Regulatory Proteins
  • IL6 protein, human
  • Interleukin-6
  • Ki-67 Antigen
  • Neoplasm Proteins
  • Oligonucleotides, Antisense
  • Proto-Oncogene Proteins c-bcl-2
  • AKT1 protein, human
  • Proto-Oncogene Proteins c-akt
  • Caspase 3
Topics
  • Apoptosis Regulatory Proteins (biosynthesis)
  • Caspase 3 (biosynthesis)
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Interleukin-6 (biosynthesis)
  • Ki-67 Antigen (biosynthesis, genetics)
  • Male
  • Neoplasm Proteins (biosynthesis, genetics)
  • Oligonucleotides, Antisense (therapeutic use)
  • Prostatic Neoplasms (genetics, pathology, therapy)
  • Proto-Oncogene Proteins c-akt (biosynthesis, genetics)
  • Proto-Oncogene Proteins c-bcl-2 (antagonists & inhibitors, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: